Prognostic Impact of Fasting Plasma Glucose on Mortality and Re-Hospitalization in Patients with Acute Heart Failure

Chen, Yu Yang; Chen, Yuan; Liang, Shu; Su, Zi Zhuo; Shu, Xiao; Zhang, Hai; Wan, Siu Hin; Wang, Jing Feng; Xie, Shuang

doi:10.4103/0366-6999.239310

Cited by 7 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, after applying the inclusion and exclusion criteria, 12 studies comprising 28 643 participants with a median follow-up duration of 2.3 years were included for analysis. [15][16][17][18][29][30][31][32][33][34][35][36] The prevalence of prediabetes in the included studies ranged from 9.6% to 43.0%. The key characteristics of the included studies are presented in Online Supplementary Files S2.…”

Section: Studies Retrieved and Characteristicsmentioning

confidence: 99%

Association between prediabetes and adverse outcomes in heart failure

Mai

Wen

Qiu

et al. 2021

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aims Patients with heart failure (HF) and with diabetes experienced significantly worse outcomes than those without diabetes. However, data on the prognostic impact of prediabetes in HF are inconclusive. This meta‐analysis aimed to explore the association between prediabetes and the risk of all‐cause mortality and adverse cardiac outcomes in patients with HF. Materials and methods We searched multiple electronic databases (PubMed, Embase and Google Scholar) for relevant studies up to 31 March 2021. Studies were included for analysis if multivariable adjusted relative risks of adverse outcomes were reported in patients with prediabetes and with HF compared with those with normoglycaemia. Random‐effects models were used to calculate the pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Results Twelve studies comprising 28 643 patients with HF reported the risk of all‐cause mortality and cardiac outcomes associated with prediabetes. The prevalence of prediabetes ranged from 9.6% to 37.2%. After a median follow‐up duration of 2.3 years, patients with HF and with prediabetes were associated with an increased risk of all‐cause mortality (HR 1.29, 95% CI 1.06‐1.58), cardiovascular mortality (HR 1.59, 95% CI 1.09‐2.32), HF hospitalization (HR 1.33, 95% CI 1.09‐1.61), all‐cause mortality and/or HF hospitalization (HR 1.22, 95% CI 1.01‐1.47), as well as cardiovascular mortality and/or HF hospitalization (HR 1.21, 95% CI 1.07‐1.37). Conclusions Prediabetes is associated with a worse prognosis in patients with HF. Further risk stratification and effective treatment strategies are needed in patients with prediabetes and with HF to improve the prognosis.

show abstract

Section: Studies Retrieved and Characteristicsmentioning

confidence: 99%

Association between prediabetes and adverse outcomes in heart failure

Mai

Wen

Qiu

et al. 2021

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Thus, we did not include those studies in our analysis. Finally, there were 74 studies 27–100 and 38 studies 85,101–137 in which we could estimate RRs for new‐onset and recurrent HF, respectively, in relation to DM. One study 85 examined both new‐onset and recurrent HF risk.…”

Section: Resultsmentioning

confidence: 99%

Diabetes mellitus and risk of new‐onset and recurrent heart failure: a systematic review and meta‐analysis

et al. 2020

View full text Add to dashboard Cite

Despite mounting evidence of the positive relationship between diabetes mellitus (DM) and heart failure (HF), the entire context of the magnitude of risk for HF in relation to DM remains insufficiently understood. The principal reason is because new-onset HF (HF occurring in participants without a history of HF) and recurrent HF (HF re-occurring in patients with a history of HF) are not discriminated. This meta-analysis aims to comprehensively and separately assess the risk of new-onset and recurrent HF depending on the presence or absence of DM. We systematically searched cohort studies that examined the relationship between DM and new-onset or recurrent HF using EMBASE and MEDLINE (from 1 Jan 1950 to 28 Jul 2019). The risk ratio (RR) for HF in individuals with DM compared with those without DM was pooled with a random-effects model. Seventy-four and 38 eligible studies presented data on RRs for new-onset and recurrent HF, respectively. For new-onset HF, the pooled RR [95% confidence interval (CI)] of 69 studies that examined HF as a whole [i.e. combining HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF)] was 2.14 (1.96-2.34). The large between-study heterogeneity (I 2 = 99.7%, P < 0.001) was significantly explained by mean age [pooled RR (95% CI) 2.60 (2.38-2.84) for mean age < 60 years vs. pooled RR (95% CI) 1.95 (1.79-2.13) for mean age ≥ 60 years] (P < 0.001). Pooled RRs (95% CI) of seven and eight studies, respectively, that separately examined HFpEF and HFrEF risk were 2.22 (2.02-2.43) for HFpEF and 2.73 (2.71-2.75) for HFrEF. The risk magnitudes between HFpEF and HFrEF were not significantly different in studies that examined both HFpEF and HFrEF risks (P = 0.86). For recurrent HF, pooled RR (95% CI) of the 38 studies was 1.39 (1.33-1.45). The large between-study heterogeneity (I 2 = 80.1%, P < 0.001) was significantly explained by the proportion of men [pooled RR (95% CI) 1.53 (1.40-1.68) for < 65% men vs. 1.32 (1.25-1.39) for ≥65% men (P = 0.01)] or the large pooled RR for studies of only participants with HFpEF [pooled RR (95% CI), 1.73 (1.32-2.26) (P = 0.002)]. Results indicate that DM is a significant risk factor for both new-onset and recurrent HF. It is suggested that the risk magnitude is large for new-onset HF especially in young populations and for recurrent HF especially in women or individuals with HFpEF. DM is associated with future HFpEF and HFrEF to the same extent.

show abstract

“…The diagnosis of diabetes referred to the American Diabetes Association, including fasting glucose ≥ 7.0 mmol/L, HbA1c ≥ 6.5%, or the use of any antidiabetic medication or self-reported diagnosis history of diabetes [ 22 ]. We used fasting glucose as a marker of glycemic control [ 23 , 24 ]: good and poor glycemic control were defined as fasting glucose < 7.0 mmol/L and ≥ 7.0 mmol/L, respectively. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration serum creatinine Eq.…”

Section: Methodsmentioning

confidence: 99%

Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes

Zhang

et al. 2022

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Arterial stiffness, glycemic control and blood pressure are risk factors of macrovascular complications in type 2 diabetes. This study aimed to investigate the combined association of arterial stiffness, glycemic control and hypertension status with the occurrence of diabetic macrovascular complication. Methods A total of 1870 patients of diabetes were enrolled from Beijing Health Management Cohort between 2008 and 2018 as baseline, and then followed for macrovascular complication onset. We proposed a composite risk score (0–4) by arterial stiffness severity, pool glycemic control and hypertension status. Cox model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI). Results The mean age (SD) of this population was 59.90 (12.29) years. During a median follow-up of 4.0 years, 359 (19.2%) patients developed macrovascular complication. Compared to the normal arterial stiffness and good glycemic control group, patients with severe arterial stiffness and pool glycemic control had the highest risk of macrovascular complications (HR: 2.73; 95% CI: 1.42–5.25). Similarly, those of severe arterial stiffness and hypertension had the highest risk (HR: 2.69; 95% CI: 1.61–4.50). Patients of the composite score > 2 had a significantly increased risk of macrovascular complication. Conclusion This study suggested the clinical importance of combined evaluation of arterial stiffness, glycemic control and hypertension status for the risk stratification and management of macrovascular complication of type 2 diabetes.

show abstract

Prognostic Impact of Fasting Plasma Glucose on Mortality and Re-Hospitalization in Patients with Acute Heart Failure

Cited by 7 publications

References 36 publications

Association between prediabetes and adverse outcomes in heart failure

Association between prediabetes and adverse outcomes in heart failure

Diabetes mellitus and risk of new‐onset and recurrent heart failure: a systematic review and meta‐analysis

Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes

Contact Info

Product

Resources

About